Dermatology Risks Are Likely Different for JAK Inhibitors
Black box warnings for JAK inhibitors arise from rheumatoid arthritis studies, leading one expert to question the risk-benefit relevance to dermatologic diseases, particularly in younger patients.
Medscape Medical News
source https://www.medscape.com/viewarticle/989840?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/989840?src=rss
Comments
Post a Comment